These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6215895)

  • 1. Cefoperazone: regression analysis, disk content, and disk susceptibility testing considerations.
    Wright DN; Welch DF; Saxon BA; Clark SJ; Matsen JM
    Antimicrob Agents Chemother; 1982 Sep; 22(3):493-8. PubMed ID: 6215895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits.
    Jones RN; Gavan TL; Barry AL; Thornsberry C; Gibbs DL
    J Clin Microbiol; 1982 May; 15(5):777-86. PubMed ID: 6212596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.
    Ayers LW; Jones RN; Barry AL; Thornsberry C; Fuchs PC; Gavan TL; Gerlach EH; Sommers HM
    Antimicrob Agents Chemother; 1982 Nov; 22(5):859-77. PubMed ID: 6983862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefpirome (HR810) disk diffusion susceptibility tests: confirmation of interpretive criteria using cefotaxime and cefoperazone-resistant strains and effects of blood supplemented media.
    Jones RN; Barry AL; Thornsberry C
    Diagn Microbiol Infect Dis; 1986 Apr; 4(4):345-9. PubMed ID: 3698547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-strain regression analysis for determination of interpretive breakpoints for cefoperazone disk diffusion susceptibility testing.
    Kronvall G
    J Clin Microbiol; 1983 Jun; 17(6):975-80. PubMed ID: 6223938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.
    Fuchs PC; Barry AL; Thornsberry C; Jones RN; Gavan TL; Gerlach EH; Sommers HM
    Antimicrob Agents Chemother; 1980 Jul; 18(1):88-93. PubMed ID: 6251750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazone.
    Thornsberry C; Barry AL; Jones RN; Baker CN; Badal RE
    J Clin Microbiol; 1982 May; 15(5):769-76. PubMed ID: 6212595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.
    Bradford PA; Sanders CC
    Antimicrob Agents Chemother; 1992 Feb; 36(2):394-400. PubMed ID: 1605604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of in vitro antimicrobial activity of cefazolin alone and in combination with cefmetazole or flomoxef using agar dilution method and disk diffusion method].
    Matsuo K; Uete T
    Jpn J Antibiot; 1992 Oct; 45(10):1253-66. PubMed ID: 1479676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of bacterial pathogens to cefotetan judged by MIC and disc tests.
    Grimm H
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():37-43. PubMed ID: 6573324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpretive standards for disk susceptibility tests with Sch 21420 and amikacin.
    Barry AL; Thornsberry C; Jones RN; Gerlach EH
    Antimicrob Agents Chemother; 1980 Oct; 18(4):616-21. PubMed ID: 7447420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antimicrobial susceptibility testing using 30 microG and 75 microG U63196-E (cefpimizole AC-1370) disks.
    Jones RN; Thornsberry C; Barry AL
    Diagn Microbiol Infect Dis; 1985 Jan; 3(1):87-92. PubMed ID: 3967476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proposed disk diffusion susceptibility criteria for ofloxacin.
    Fuchs PC; Barry AL; Jones RN; Thornsberry C
    J Clin Microbiol; 1985 Aug; 22(2):310-1. PubMed ID: 3861612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Statistical regression analysis for four new cephalosporins (author's transl)].
    Sirot D; Glanddier Y; Chanal M; Sirot J; Cluzel R
    Pathol Biol (Paris); 1982 Jun; 30(6):357-62. PubMed ID: 6287389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin.
    Fuchs PC; Jones RN; Barry AL; Thornsberry C
    J Clin Microbiol; 1986 Mar; 23(3):634-6. PubMed ID: 3754266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin.
    Jones RN; Barry AL
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1576-82. PubMed ID: 3190185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aztreonam: correlation between disk diffusion and agar plate dilutions susceptibility tests.
    Toma EC; Morisset R; Phaneuf D; Poisson M
    Chemotherapy; 1985; 31(6):451-5. PubMed ID: 4075858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of moxalactam (LY127935) susceptibility tests by disk diffusion and agar plate dilution methods.
    Hall WH; Opfer BJ
    Antimicrob Agents Chemother; 1981 Jan; 19(1):130-3. PubMed ID: 6454380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical laboratory approach for estimating effective administrative dose of cefoperazone. Evaluation of disc susceptibility test and its interpretation system].
    Matsuo K; Uete T
    Jpn J Antibiot; 1988 Oct; 41(10):1418-29. PubMed ID: 3204655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piperacillin susceptibility tests by the single-disk agar diffusion technique.
    Barry AL; Thornsberry C; Badal RE; Baker CN; Jones RN; Gerlach EH
    Antimicrob Agents Chemother; 1979 Sep; 16(3):378-85. PubMed ID: 507794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.